Clinical trial

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

NCT01509742

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record liraglutide Normalized identity: liraglutideView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2001-04-01

PhasePHASE1

Conditions

Diabetesverified · MONDO: diabetes mellitus

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Interventions

liraglutideDRUG · verified · RxNorm: liraglutide

placeboDRUG

Sponsors & collaborators

Novo Nordisk A/Slead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01509742 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.